See the DrugPatentWatch profile for xolair
What is Xolair’s age distribution in clinical data?
“IQVIA Xolair age distribution” can mean two different things: (1) patient ages in Xolair’s clinical trials, or (2) how IQVIA reports Xolair patients by age in real-world prescribing data. The information provided here does not include either kind of age breakdown, so I can’t state specific percentages or age bands.
Are you asking about trial participants’ ages or real-world patients by age?
If you tell me which one you mean, I can help you interpret what to look for and how it’s typically presented:
- Trial age distribution: usually reported as mean/median age and an age range, sometimes with counts by age group (for example, pediatrics vs adults).
- Real-world (IQVIA) age distribution: typically shown as a percentage of treated patients (or prescriptions) by age band using claims/EMR data.
Where can IQVIA age distribution for Xolair usually be found?
IQVIA age distribution is often generated from commercial datasets or reports that aggregate treated populations. To pull the right numbers, you’d typically need:
- The geography (e.g., US, EU5)
- The time window (year or range)
- The metric (patients vs prescriptions; prevalence vs incident users)
- The age banding scheme (e.g., 0–17, 18–34, 35–49, 50–64, 65+)
Quick check: do you mean Xolair (omalizumab) for asthma or for another indication?
Xolair is used for multiple conditions (for example, allergic asthma, chronic spontaneous urticaria). Age mix can differ by indication, so the indication matters for any age distribution.
Tell me what you’re looking for and I’ll narrow it down
Reply with:
1) US or another country/region
2) years (or “latest available”)
3) patients or prescriptions
4) indication (asthma, urticaria, etc.)
5) whether you mean clinical trial ages or IQVIA real-world ages
Then I can format the age distribution in a way that matches your intended use.